In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Weigel, Marion T ^a   Dahmke, Linda ^a   Schem, Christian ^a   Bauerschlag, Dirk O ^a,b   Weber, Katrin ^a   Niehoff, Peter ^a   Bauer, Maret ^a   Strauss, Alexander ^a   Jonat, Walter ^a   Maass, Nicolai ^a,b   Mundhenke, Christoph ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; COBALT; IRIDIUM; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL CULTURE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN MCF 7; CHEMOSENSITIVITY; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IRRADIATION; PHOSPHORYLATION; PROTEIN EXPRESSION; RADIATION; RADIOSENSITIVITY; BREAST TUMOR; CELL ADHESION; CELL MOTION; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; FEMALE; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIATION DOSE; RADIATION EXPOSURE; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; COBALT RADIOISOTOPES; COMBINED MODALITY THERAPY; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IRIDIUM RADIOISOTOPES; PHOSPHORYLATION; PIPERAZINES; PYRIMIDINES; RADIATION TOLERANCE; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 77955295899     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-412     Document Type: Article

References (60)

1. Niehoff P, et al. Breast irradiation with brachytherapy: approved techniques and new concepts. Minerva Ginecol 2007, 59(4):377-86.
2. Vlahovic G, Crawford J. Activation of tyrosine kinases in cancer. Oncologist 2003, 8(6):531-8. 10.1634/theoncologist.8-6-531, 14657531.
3. Nahta R, Hortobagyi GN, Esteva FJ. Growth factor receptors in breast cancer: potential for therapeutic intervention. Oncologist 2003, 8(1):5-17. 10.1634/theoncologist.8-1-5, 12604728.
4. Fong TA, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999, 59(1):99-106.
5. Noble ME, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science 2004, 303(5665):1800-5. 10.1126/science.1095920, 15031492.
6. Clarke M, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 366(9503):2087-106.
7. Bartelink H, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 2007, 25(22):3259-65. 10.1200/JCO.2007.11.4991, 17577015.
8. Baranowska-Kortylewicz J, et al. Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy. Cancer Res 2005, 65(17):7824-31. 1363769, 16140951.
9. Mendel DB, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9(1):327-37.
10. Buchdunger E, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000, 295(1):139-45.
11. Druker BJ. Imatinib as a paradigm of targeted therapies. Adv Cancer Res 2004, 91:1-30. full_text, 15327887.
12. Heinrich MC, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000, 96(3):925-32.
13. Pietras RJ. Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature. Breast J 2003, 9(5):361-73. 10.1046/j.1524-4741.2003.09510.x, 12968955.
14. Attoub S, et al. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer Res 2002, 62(17):4879-83.
15. Antoniades HN, et al. Malignant epithelial cells in primary human lung carcinomas coexpress in vivo platelet-derived growth factor (PDGF) and PDGF receptor mRNAs and their protein products. Proc Natl Acad Sci USA 1992, 89(9):3942-6. 10.1073/pnas.89.9.3942, 525607, 1315044.
16. Fudge K, Bostwick DG, Stearns ME. Platelet-derived growth factor A and B chains and the alpha and beta receptors in prostatic intraepithelial neoplasia. Prostate 1996, 29(5):282-6. 10.1002/(SICI)1097-0045(199611)29:5<282::AID-PROS2>3.0.CO;2-C, 8899000.
17. Lindmark G, et al. Stromal expression of platelet-derived growth factor beta-receptor and platelet-derived growth factor B-chain in colorectal cancer. Lab Invest 1993, 69(6):682-9.
18. Schiffer CA. Signal transduction inhibition: changing paradigms in cancer care. Semin Oncol 2001, 28(5 Suppl 17):34-9. 10.1053/sonc.2001.29183, 11740805.
19. Mundhenke C, et al. Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects. J Cancer Res Clin Oncol 2008,
20. Lev DC, et al. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. Clin Cancer Res 2005, 11(1):306-14.
21. de Jong JS, et al. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops. J Pathol 1998, 184(1):44-52. 10.1002/(SICI)1096-9896(199801)184:1<44::AID-PATH984>3.0.CO;2-H, 9582526.
22. Ariad S, Seymour L, Bezwoda WR. Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: correlation with stage and rate of progression. Breast Cancer Res Treat 1991, 20(1):11-7. 10.1007/BF01833352, 1667486.
23. Seymour L, Bezwoda WR. Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer. Breast Cancer Res Treat 1994, 32(2):229-33. 10.1007/BF00665774, 7865852.
24. Heldin CH, Ostman A, Ronnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta 1998, 1378(1):F79-113.
25. Kennedy SG, et al. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev 1997, 11(6):701-13. 10.1101/gad.11.6.701, 9087425.
26. Uehara H, et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 2003, 95(6):458-70. 10.1093/jnci/95.6.458, 12644539.
27. Apte SM, et al. Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin Cancer Res 2004, 10(3):897-908. 10.1158/1078-0432.CCR-1151-3, 14871965.
28. Langley RR, et al. Activation of the platelet-derived growth factor-receptor enhances survival of murine bone endothelial cells. Cancer Res 2004, 64(11):3727-30. 10.1158/0008-5472.CAN-03-3863, 15172974.
29. Pietras K, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001, 61(7):2929-34.
30. Pietras K, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002, 62(19):5476-84.
31. Weigel MT, et al. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling. Cancer Lett 2008,
32. Chou TC. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 1976, 59(2):253-76. 10.1016/0022-5193(76)90169-7, 957690.
33. Chou TC, Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 1981, 115(1):207-16. 10.1111/j.1432-1033.1981.tb06218.x, 7227366.
34. Roussidis AE, et al. The importance of c-Kit and PDGF receptors as potential targets for molecular therapy in breast cancer. Curr Med Chem 2007, 14(7):735-43. 10.2174/092986707780090963, 17346159.
35. Carvalho I, et al. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res 2005, 7(5):R788-95. 10.1186/bcr1304, 1242156, 16168125.
36. Bhardwaj B, et al. Localization of platelet-derived growth factor beta receptor expression in the periepithelial stroma of human breast carcinoma. Clin Cancer Res 1996, 2(4):773-82.
37. Paulsson J, et al. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 2009, 175(1):334-41. 10.2353/ajpath.2009.081030, 2708819, 19498003.
38. Jechlinger M, et al. Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest 2006, 116(6):1561-70. 10.1172/JCI24652, 1469776, 16741576.
39. Zhu L, et al. Possible predictive markers related to micro-metastasis in breast cancer patients. Oncol Rep 2006, 15(5):1217-23.
40. Skinner MA, Safford SD, Freemerman AJ. RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571. Anticancer Res 2003, 23(5A):3601-6.
41. Li J, et al. Effects of STI571 (gleevec) on pancreatic cancer cell growth. Mol Cancer 2003, 2(32). 212230, 14521721.
42. Druker BJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344(14):1031-7. 10.1056/NEJM200104053441401, 11287972.
43. Krystal GW, et al. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 2000, 6(8):3319-26.
44. McHowat J, et al. Clinical concentrations of doxorubicin inhibit activity of myocardial membrane-associated, calcium-independent phospholipase A(2). Cancer Res 2001, 61(10):4024-9.
45. Blagosklonny MV, Fojo T. Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer 1999, 83(2):151-6. 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5, 10471519.
46. Yerushalmi R, et al. Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro. Exp Oncol 2007, 29(2):126-31.
47. Katayama R, et al. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma. Cancer Chemother Pharmacol 2004, 54(1):25-33. 10.1007/s00280-004-0780-7, 15108021.
48. Modi S, et al. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat 2005, 90(2):157-63. 10.1007/s10549-004-3974-0, 15803362.
49. Cristofanilli M, et al. Imatinib mesylate (Gleevec(R)) in advanced breast cancer-expressing C-Kit or PDGFR-{beta}: clinical activity and biological correlations. Ann Oncol 2008, 2735063, 18515258.
50. Yardley DA, et al. Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer. Clin Breast Cancer 2009, 9(4):237-42. 10.3816/CBC.2009.n.040, 19933079.
51. Fertil B, Malaise EP. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys 1985, 11(9):1699-707.
52. Matthews JH, Meeker BE, Chapman JD. Response of human tumor cell lines in vitro to fractionated irradiation. Int J Radiat Oncol Biol Phys 1989, 16(1):133-8.
53. Geng L, et al. STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma. Int J Radiat Oncol Biol Phys 2006, 64(1):263-71.
54. Servidei T, et al. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation. J Cell Physiol 2006, 208(1):220-8. 10.1002/jcp.20659, 16575905.
55. Chung HW, et al. Radiosensitization effect of STI-571 on pancreatic cancer cells in vitro. Int J Radiat Oncol Biol Phys 2009, 75(3):862-9.
56. Russell JS, et al. Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res 2003, 63(21):7377-83.
57. Holdhoff M, et al. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis 2005, 34(2):181-5. 10.1016/j.bcmd.2004.11.006, 15727903.
58. Oertel S, et al. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec). Strahlenther Onkol 2006, 182(7):400-7. 10.1007/s00066-006-1445-8, 16826359.
59. Pietras K. Increasing tumor uptake of anticancer drugs with imatinib. Semin Oncol 2004, 31(2 Suppl 6):18-23. 10.1053/j.seminoncol.2004.03.036, 15176000.
60. Matei D, Chang DD, Jeng MH. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clin Cancer Res 2004, 10(2):681-90. 10.1158/1078-0432.CCR-0754-03, 14760091.